Filing Details
- Accession Number:
- 0001209191-23-032034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-24 21:00:18
- Reporting Period:
- 2023-05-22
- Accepted Time:
- 2023-05-24 21:00:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
899460 | Mannkind Corp | MNKD | Pharmaceutical Preparations (2834) | 133607736 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1712601 | B. Steven Binder | 1 Casper Street Danbury CT 06810 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $.01 Par Value | Acquisiton | 2023-05-22 | 400,000 | $4.79 | 1,113,539 | No | 4 | A | Direct | |
Common Stock, $.01 Par Value | Disposition | 2023-05-22 | 227,405 | $4.79 | 886,134 | No | 4 | F | Direct | |
Common Stock, $.01 Par Value | Disposition | 2023-05-24 | 47,810 | $4.68 | 838,324 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | S | Direct |
Footnotes
- A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020.
- Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units.
- Transaction occurred pursuant to Rule 10B5-1 Plan.